InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.
How this was made
The 30-second read
Why it matters
This reduces immediate delisting risk by confirming Nasdaq has closed the matter under Listing Rule 5550(a)(2). The main trading implication is removal of a compliance overhang; fundamental catalysts are unchanged.
Market read
A compliance resolution can support the stock by lowering tail-risk, but it is not a new operating catalyst.
What to watch
Traders should monitor whether the bid price stays above $1 for sustained periods and whether any other Nasdaq listing criteria (e.g., market value, shareholders’ equity) remain at risk.
Background
InMed was previously notified (Mar 27, 2026) that it failed to maintain Nasdaq’s $1.00 minimum bid price for 30 consecutive business days; it regained compliance after meeting the 10 consecutive days threshold (May 19–Jun 2).
Ticker impact
Nasdaq notified InMed it regained compliance with the $1.00 minimum bid price rule, closing the listing deficiency matter.
Mild positive bias possible; follow-through likely limited unless bid-price stability persists.
The news is a compliance/overhang resolution (not earnings or pipeline data). Traders may re-rate risk, but the company’s core risk remains bid-price volatility and clinical/regulatory execution.
Market effects
For micro-cap biopharma, Nasdaq compliance headlines can temporarily affect risk premia across similar bid-price-sensitive names.
Primarily US-listed micro-cap sentiment; limited spillover beyond Nasdaq-listed small caps.
Low—this is a venue-specific listing-rule resolution, not a cross-border regulatory or clinical event.
Counterpoint
Compliance closure may be largely mechanical; if the stock trades back below $1 quickly, the market may treat this as temporary relief.
Key entities
- companyInMed Pharmaceuticals Inc.
Nasdaq-listed pharmaceutical company that regained compliance with the minimum bid price requirement.
- regulator/venueNasdaq Stock Market LLC
Listing authority that determined InMed met the 10 consecutive business days bid-price condition and closed the matter.
